173 related articles for article (PubMed ID: 9915099)
21. Educational strategies to promote evidence-based community pharmacy practice: a cluster randomized controlled trial (RCT).
Watson MC; Bond CM; Grimshaw JM; Mollison J; Ludbrook A; Walker AE
Fam Pract; 2002 Oct; 19(5):529-36. PubMed ID: 12356708
[TBL] [Abstract][Full Text] [Related]
22. Consumers' Perceptions About Pharmaceutical Care Provided by Community Pharmacists in China in Relation to Over-the-Counter Drugs: A Qualitative Study.
Chen H; Ung COL; Chi P; Wu J; Tang D; Hu H
Inquiry; 2018; 55():46958018793292. PubMed ID: 30095016
[TBL] [Abstract][Full Text] [Related]
23. The effect of the Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy.
Sullivan PW; Nair KV; Patel BV
Am J Manag Care; 2005 Jun; 11(6):374-82. PubMed ID: 15974556
[TBL] [Abstract][Full Text] [Related]
24. Surveillance and uncertainty: community pharmacy responses to over the counter medicine abuse.
Cooper R
Health Soc Care Community; 2013 May; 21(3):254-62. PubMed ID: 23320510
[TBL] [Abstract][Full Text] [Related]
25. Dispensing physicians and prescribing pharmacists: economic considerations for the UK.
Ryan M; Bond C
Pharmacoeconomics; 1994 Jan; 5(1):8-17. PubMed ID: 10146862
[TBL] [Abstract][Full Text] [Related]
26. Substitution between prescribed and over-the-counter medications.
Leibowitz A
Med Care; 1989 Jan; 27(1):85-94. PubMed ID: 2911221
[TBL] [Abstract][Full Text] [Related]
27. Trends in prescribing for vulvovaginal candidiasis in the United States.
McCaig LF; McNeil MM
Pharmacoepidemiol Drug Saf; 2005 Feb; 14(2):113-20. PubMed ID: 15386715
[TBL] [Abstract][Full Text] [Related]
28. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis.
Ferris DG; Nyirjesy P; Sobel JD; Soper D; Pavletic A; Litaker MS
Obstet Gynecol; 2002 Mar; 99(3):419-25. PubMed ID: 11864668
[TBL] [Abstract][Full Text] [Related]
29. Promoting safe and effective use of OTC medications: CHPA-GSA National Summit.
Albert SM; Bix L; Bridgeman MM; Carstensen LL; Dyer-Chamberlain M; Neafsey PJ; Wolf MS
Gerontologist; 2014 Dec; 54(6):909-18. PubMed ID: 24846884
[TBL] [Abstract][Full Text] [Related]
30. The "prescription-to-OTC switch" movement. Its effects on antifungal vaginitis preparations.
Lipsky MS; Waters T
Arch Fam Med; 1999; 8(4):297-300. PubMed ID: 10418534
[TBL] [Abstract][Full Text] [Related]
31. Pharmacists' adoption into practice of newly reclassified medicines from diverse therapeutic areas in Scotland: a quantitative study of factors associated with decision-making.
Paudyal V; Hansford D; Cunningham S; Stewart D
Res Social Adm Pharm; 2014; 10(1):88-105. PubMed ID: 23665077
[TBL] [Abstract][Full Text] [Related]
32. Bypassing the middleman: a grounded theory of women's self-care for vaginal symptoms.
Theroux R
Health Care Women Int; 2002; 23(5):417-31. PubMed ID: 12171693
[TBL] [Abstract][Full Text] [Related]
33. A Detailed Analysis of the Past 20 Years of US FDA-Approved Prescription to Over-the-Counter Switches.
Fisher M; Rawal K
Ther Innov Regul Sci; 2023 Sep; 57(5):1074-1080. PubMed ID: 37357243
[TBL] [Abstract][Full Text] [Related]
34. Use of Proprietary Names by Prescribers When Prescribing Over-the-Counter (OTC) Drug Products.
Tu CM
Ther Innov Regul Sci; 2019 Jan; 53(1):132-137. PubMed ID: 29714596
[TBL] [Abstract][Full Text] [Related]
35. APhA-ASIM statement on prescription writing and prescription labeling.
J Am Pharm Assoc; 1974 Dec; 14(12):654. PubMed ID: 4436514
[No Abstract] [Full Text] [Related]
36. Pharmacy consultation and over-the-counter medication purchasing outcomes. Over-the-Counter Medication Intervention Project Team.
Sclar DA; Robison LM; Skaer TL
J Clin Pharm Ther; 1996 Jun; 21(3):177-84. PubMed ID: 8873852
[TBL] [Abstract][Full Text] [Related]
37. ASHP national survey of pharmacy practice in hospital settings: Prescribing and transcribing-2016.
Pedersen CA; Schneider PJ; Scheckelhoff DJ
Am J Health Syst Pharm; 2017 Sep; 74(17):1336-1352. PubMed ID: 28743758
[TBL] [Abstract][Full Text] [Related]
38. Changing oral contraceptives from prescription to over-the-counter status: an opinion statement of the Women's Health Practice and Research Network of the American College of Clinical Pharmacy.
McIntosh J; Rafie S; Wasik M; McBane S; Lodise NM; El-Ibiary SY; Forinash A; Kachlic MD; Rowe E; Besinque K
Pharmacotherapy; 2011 Apr; 31(4):424-37. PubMed ID: 21449630
[TBL] [Abstract][Full Text] [Related]
39. Report of the APhA and APhA-ASP Houses of Delegates.
Bzowyckyj A; Oestreich J; Kirk LM
J Am Pharm Assoc (2003); 2015; 55(4):340, 342-4, 346-7. PubMed ID: 26161477
[No Abstract] [Full Text] [Related]
40. The risks and benefits of an Rx-to-OTC switch. The case of over-the-counter H2-blockers.
Oster G; Huse DM; Delea TE; Colditz GA; Richter JM
Med Care; 1990 Sep; 28(9):834-52. PubMed ID: 1976142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
